Hydrogen peroxide
Eskata, Sibnayal (hydrogen peroxide) is a small molecule pharmaceutical. Hydrogen peroxide was first approved as Eskata on 2017-12-14. It is used to treat surgical wound infection in the USA. It has been approved in Europe to treat renal tubular acidosis. It is known to target transient receptor potential cation channel subfamily M member 2 and transient receptor potential cation channel subfamily A member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrogen peroxide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ESKATA | Aclaris Therapeutics | N-209305 DISCN | 2017-12-14 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 16oz hydrogen peroxide | OTC monograph not final | 2020-09-25 |
| 3 hydrogen peroxide | C200263 | 2025-03-05 |
| 3 percent hydrogen peroxide | OTC monograph not final | 2020-10-12 |
| 3% hydrogen peroxide | OTC monograph not final | 2022-01-13 |
| 32oz hydrogen peroxide | OTC monograph not final | 2020-09-25 |
| american red cross 3 hydrogen peroxide | C200263 | 2024-12-20 |
| american red cross 6oz, 3% hydrogen peroxide | C200263 | 2024-12-13 |
| american red cross hydrogen peroxide 3% 6oz | C200263 | 2024-12-12 |
| american safety first aid antispetic | C200263 | 2024-01-15 |
| aplicare | C200263 | 2025-04-18 |
Show 132 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| surgical wound infection | — | D013530 | — |
Agency Specific
FDA
EMA
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB02: Hydrogen peroxide
D: Dermatologicals
— D08: Antiseptics and disinfectants
— D08A: Antiseptics and disinfectants
— D08AX: Other antiseptics and disinfectants in atc
— D08AX01: Hydrogen peroxide
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AX: Other dermatological preparations in atc
— D11AX25: Hydrogen peroxide
S: Sensory organ drugs
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA06: Hydrogen peroxide
HCPCS
No data
Clinical
Clinical Trials
265 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Actinic keratosis | D055623 | — | L57.0 | 1 | 4 | 3 | 1 | — | 8 |
| Seborrheic keratosis | D017492 | EFO_0005584 | L82 | 1 | 4 | 3 | 1 | — | 8 |
| Keratosis | D007642 | — | — | 1 | 4 | 3 | 1 | — | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | — | 1 |
| Papulosquamous skin diseases | D017444 | — | L40-L45 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydrogen peroxide |
| INN | — |
| Description | Peroxides is compounds of structure ROOR'. It has a role as an oxidising agent. It contains a peroxy group. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OO |
Identifiers
| PDB | — |
| CAS-ID | 7722-84-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL71595 |
| ChEBI ID | 16240 |
| PubChem CID | 784 |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Eskata – Aclaris Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Hydrogen peroxide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 230,274 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
589 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use